Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines-Reference-Cited by-同舟云学术

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Published:2008-06-15 Issue:12 Volume:111 Page:5446-5456
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hallek Michael¹,Cheson Bruce D.²,Catovsky Daniel³,Caligaris-Cappio Federico⁴,Dighiero Guillaume⁵,Döhner Hartmut⁶,Hillmen Peter⁷,Keating Michael J.⁸,Montserrat Emili⁹,Rai Kanti R.¹⁰,Kipps Thomas J.¹¹

Affiliation:

1. Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany;

2. Georgetown University Hospital, Lombardi Cancer Center, Washington, DC;

3. Institute of Cancer Research, London, United Kingdom;

4. Universita Vita-Salute Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Milano, Italy;

5. Institute Pasteur, Montevideo, Uruguay;

6. University of Ulm, Ulm, Germany;

7. St James's Institute of Oncology, Leeds, United Kingdom;

8. Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston;

9. Hospital Clinic, IDIBAPS, Barcelona, Spain;

10. Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; and

11. Rebecca and John Moores Cancer Center, University of California–San Diego, La Jolla

Abstract

Abstract Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute–sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/111/12/5446/1298113/zh802508005446.pdf

Reference77 articles.

1. Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL): recommendations of the NCI-sponsored working group.;Cheson;Am J Hematol,1988

2. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.;Cheson;Blood,1996

3. Chronic lymphocytic leukemia/small lymphocytic lymphoma.;Müller-Hermelink,2001

4. T-cell prolymphocytic leukaemia.;Catovsky,2001

5. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia: IV. Analysis of survival and prognostic features.;Melo;Br J Haematol,1986

Cited by 2774 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management;Current Cancer Therapy Reviews;2025-01

2. Global burden, risk factor analysis, and prediction study of leukaemia from 1990 to 2030;Journal of Global Health;2024-08-23

3. IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence;Blood Advances;2024-08-14

4. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial;Nature Communications;2024-08-09

5. Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT);Leukemia Research;2024-08